57797-97-4

Basic information

• Product Name: 8-CHLORO-4-HYDROXYQUINOLINE
• Synonyms: 8-CHLORO-4-HYDROXYQUINOLINE;8-CHLORO-4-QUINOLINOL;4-HYDROXY-8-CHLOROQUINOLINE;4-Chloro-4-hydroxyquinoline;8-Chloroquinolin-4-ol
• CAS NO: 57797-97-4
• Molecular Formula: C₉H₆ClNO
• Molecular Weight: 179.6
• EINECS: -0
• Mol File: 57797-97-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 300.8°Cat760mmHg
• Flash Point: 135.7°C
• Appearance: /
• Density: 1.339g/cm³
• Vapor Pressure: 0.00109mmHg at 25°C
• Refractive Index: 1.608
• CAS DataBase Reference: 8-CHLORO-4-HYDROXYQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-CHLORO-4-HYDROXYQUINOLINE(57797-97-4)
• EPA Substance Registry System: 8-CHLORO-4-HYDROXYQUINOLINE(57797-97-4)

Safety Data

• Hazard Codes: T
• Statements: 25-41
• Safety Statements: 26-39-45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 57797-97-4(Hazardous Substances Data)

Usage

Chemical Properties

Off White powder

InChI:InChI=1/C9H6ClNO/c10-7-3-1-2-6-8(12)4-5-11-9(6)7/h1-5H,(H,11,12)

Upstream product

• 35966-16-6 8-chloro-4-hydroxy-quinoline-3-carboxylic acid 
• 95-51-2 o-chloroaniline 
• 762-42-5 dimethyl acetylenedicarboxylate 
• 383895-05-4 5-[(2-chloro-phenylamino)-methylene]-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 19056-78-1 2-[(2-chlorophenylamino)-methylene]-malonic acid diethyl ester 
• 73987-37-8 8-chloro-4-hydroxy-quinoline-3-carboxylic acid ethyl ester 
• 137-04-2 2-chloroaniline hydrochloride 
• 611-33-6 8-chloroquinoline 

Downstream Products

• 21617-12-9 4,8-dichloroquinoline 

Relevant articles and documents

A one-pot, two-step synthesis of 3-deazacanthin-4-ones via sequential Pd-catalyzed Suzuki-Miyaura and Cu-catalyzed Buchwald-Hartwig reactions

3-Deazacanthin-4-one and nine analogues, including the 8-aza analogue, were prepared rapidly and in high yields from 8-iodoquinolones and 2-chloro(het)arylboronic acids. The strategy involves construction of the central B ring via concomitant Pd-catalyzed

HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS

The present invention relates to compounds of formula (I): wherein R1, R2, R4, n and m are as defined herein and R3 is selected from: (i) -C(O)OR31 wherein R31 is (C1-6)alkyl or aryl, wherein the (C1-6)alkyl is optionally substituted with one to three halogen substituents; (ii) -C(O)NR32R33, wherein R32 and R33 are each independently selected form H, (C1-6)alkyl, and Het; (iii) -SOvR34, wherein v is 1 or 2 and R34 is selected from: (C1-6)alkyl, aryl, Het, and NR32R33 wherein R32 and R33 are as defined above; and (iv) -CO(O)-R35, wherein R35 is selected from (C1-8)alkyl, (C3-7)cycloalkyl-(C1-4)alkyl, aryl, aryl-(C1-6)alkyl, Het and Het-(C1-6)alkyl, each of which are optionally substituted with one or more substituents each independently selected from halo, (C1-6)alkyl, (C3-7)cycloalkyl, aryl, Het, hydroxyl, -O-(C1-6)alkyl, -S-(C1-6)alkyl, -SO-(C1-6)alkyl, -SO2-(C1-6)alkyl, -O-aryl, -S-aryl, -SO-aryl and -SO2-aryl, wherein the aryl portion of the -O-aryl, -S-aryl, -SO-aryl and -SO2-aryl are each optionally substituted with one to five halo substituents. The present invention further relates to pharmaceutical compositions containing the compounds of formula (I) and methods for using these analogs in the treatment of HCV infection.

HEPATITIS C INHIBITOR PEPTIDE ANALOGS

The invention relates to compounds of formula (I) wherein R', R2, R3, R4, R5, R6, Y, n and m are as defined herein. The compounds are useful for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compounds of the formula (III) which can be reacted with an amide anion to produce the compounds of formula (I).